Search Within

Alexander Meyer Lesokhin

Formats
  1. Meeting Abstract (252)
  2. Journal Article (103)
  3. Research Letter (11)
  4. Review (7)
  5. Correspondence (4)
  6. Book Section (2)
  7. Editorial (2)
Groups
  1. Center for Hematologic Malignancies (381)
  2. Department of Medicine (381)
  3. Hematologic Malignancies Research (381)
  4. Hematologic Malignancies, Division of (381)
  5. Myeloma (381)
  6. Survivorship Research (225)

More Groups

People
  1. Hani Hassoun (202)
  2. Heather Landau (187)
  3. Sergio Giralt (185)
  4. David Chung (175)
  5. Neha Korde (174)
  6. Sham Mailankody (170)

More People

Years
  1. 2025 (12)
  2. 2024 (52)
  3. 2023 (77)
  4. 2022 (51)
  5. 2021 (31)
  6. 2020 (18)

More Years

Publications
  1. Blood (140)
  2. Clinical Lymphoma, Myeloma and Leukemia (57)
  3. Journal of Clinical Oncology (41)
  4. Biology of Blood and Marrow Transplantation (13)
  5. Leukemia and Lymphoma (13)
  6. Blood Advances (12)

More Publications

Publishers
  1. American Society of Hematology (152)
  2. Elsevier Inc. (79)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (26)
  5. American Association for Cancer Research (14)
  6. Taylor & Francis Group (13)

More Publishers

Results (381)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Therapy-related B-lymphoblastic leukemia evolving during lenalidomide maintenance for multiple myeloma
    Meeting Abstract

    Sae-Ow, W.; Roshal, M.; Landau, H.; Lesokhin, A.; Pichardo, J.; Park, J.; Landgren, C. O.; Maslak, P.; Dogan, A.
    Modern Pathology (2015)

    Fulltext@MSK | Save
  • PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
    Journal Article

    Ansell, S. M.; Lesokhin, A. M.; Borrello, I.; Halwani, A.; Scott, E. C.; Gutierrez, M.; Schuster, S. J.; Millenson, M. M.; Cattry, D.; Freeman, G. J.; more...
    New England Journal of Medicine (2015)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Interim analysis of a randomized phase II trial comparing continuous lenalidomide and dexamethasone to autologous stem cell transplantation in multiple myeloma patients responsive to lenalidomide and dexamethasone induction
    Meeting Abstract

    Weltz, J. I.; Landau, H.; Lendvai, N.; Chung, D. J.; Lesokhin, A. M.; Devlin, S. M.; Riedel, E.; Woo, K. M.; Stellman, A.; Chimento, D.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Efficacy and risk factors analysis of upfront autologous stem cell mobilization using plerixafor and granulocyte-colony stimulating factor (GCSF) in patients with multiple myeloma
    Meeting Abstract

    Ogunniyi, A.; Rodriguez, M.; Devlin, S. M.; Adel, N. G.; Landau, H.; Chung, D. J.; Lendvai, N.; Lesokhin, A. M.; Landgren, O.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies
    Meeting Abstract

    Lesokhin, A. M.; Ansell, S. M.; Armand, P.; Scott, E. C.; Halwani, A.; Gutierrez, M.; Millenson, M. M.; Cohen, A. D.; Schuster, S. J.; Lebovic, D.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Analysis of VDT-PACE utilization in multiple myeloma patients treated at MSKCC for relapsed disease or cytoreduction and stem cell mobilization after initial induction therapy
    Meeting Abstract

    Beyer, K.; Rosner, S.; Woo, K. M.; Devlin, S. M.; Landau, H.; Hassoun, H.; Lendvai, N.; Chung, D. J.; Adel, N. G.; Puto, M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Nivolumab in patients with relapsed or refractory Hodgkin lymphoma - Preliminary safety, efficacy and biomarker results of a phase I study
    Meeting Abstract

    Armand, P.; Ansell, S. M.; Lesokhin, A. M.; Halwani, A.; Millenson, M. M.; Schuster, S. J.; Timmerman, J.; Borrello, I.; Gutierrez, M.; Scott, E. C.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for autologous stem cell mobilization in multiple myeloma patients: An update on cost analysis study at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Afifi, S.; Adel, N. G.; Duck, E.; Devlin, S. M.; Landau, H.; Lendvai, N.; Lesokhin, A. M.; Chung, D. J.; Landgren, O.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save